Brief: Brickell Biotech Announces Publication Of Japan Pivotal Phase 3 Study Results For Sofpironium Bromide Gel, 5% In The Journal Of Dermatology
19/01/2021 13:14
Jan 19 (Reuters) - Brickell Biotech Inc BBI.O :
* BRICKELL BIOTECH ANNOUNCES PUBLICATION OF JAPAN PIVOTAL
PHASE 3
STUDY RESULTS FOR SOFPIRONIUM BROMIDE GEL, 5% (ECCLOCK®) IN THE
JOURNAL OF DERMATOLOGY
Source text for Eikon: ID:nGNX2YKXPT
Further company coverage: BBI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fresh Tracks Therapeutics
See all newsBrief: Fresh Tracks Therapeutics Announces Second Adjournment Of Special Meeting Of Stockholders
Brief: Fresh Tracks Therapeutics Intends To Seek Judicial Dissolution If Liquidation And Approved By Stockholders
Brief: Fresh Tracks Therapeutics Q3 EPS USD 0.32
Brief: Fresh Tracks Therapeutics Inc On October 10 Received A Notice From Listing Qualifications Department Of Nasdaq
U.S. STOCKS ON THE MOVE-Gold miners, Goosehead Insurance, FedEx